Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring (Jul 2023)

Amyloid beta plaque accumulation with longitudinal [18F]AZD4694 PET

  • Joseph Therriault,
  • Firoza Z. Lussier,
  • Cécile Tissot,
  • Mira Chamoun,
  • Jenna Stevenson,
  • Nesrine Rahmouni,
  • Vanessa Pallen,
  • Gleb Bezgin,
  • Stijn Servaes,
  • Peter Kunach,
  • Yi‐Ting Wang,
  • Jaime Fernandez‐Arias,
  • Marie Vermeiren,
  • Tharick A. Pascoal,
  • Gassan Massarweh,
  • Paolo Vitali,
  • Jean‐Paul Soucy,
  • Paramita Saha‐Chaudhuri,
  • Serge Gauthie,
  • Pedro Rosa‐Neto

DOI
https://doi.org/10.1002/dad2.12391
Journal volume & issue
Vol. 15, no. 3
pp. n/a – n/a

Abstract

Read online

Abstract Introduction [18F]AZD4694 is an amyloid beta (Aβ) imaging agent used in several observational studies and clinical trials. However, no studies have yet published data on longitudinal Aβ accumulation measured with [18F]AZD4694. Methods We assessed 146 individuals who were evaluated with [18F]AZD4694 at baseline and 2‐year follow‐up. We calculated annual rates of [18F]AZD4694 change for clinically defined and biomarker‐defined groups Results Cognitively unimpaired (CU) older adults displayed subtle [18F]AZD4694 standardized uptake value ratio (SUVR) accumulation over the follow‐up period. In contrast, Aβ positive CU older adults displayed higher annual [18F]AZD4694 SUVR increases. [18F]AZD4694 SUVR accumulation in Aβ positive mild cognitive impairment (MCI) and dementia was modest across the neocortex Discussion Larger increases in [18F]AZD4694 SUVR were observed in CU individuals who had abnormal amyloid positron emission tomography levels at baseline. [18F]AZD4694 can be used to monitor Aβ levels in therapeutic trials as well as clinical settings, particularly prior to initiating anti‐amyloid therapies.

Keywords